FDA Accord With Drugmakers Raises User Fees 6% to Renew Law
This article is for subscribers only.
Drugmakers such as Pfizer Inc. and Eli Lilly & Co. agreed with regulators on a 6 percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.
The deal, disclosed in part today, would renew for five years a federal law funding Food and Drug Administration evaluations of brand-name drugs. Congress must approve the accord before the law expires on Sept. 30, 2012.